Hurley Consulting Associates is a long-established, privately-held services firm specializing in clinical research and regulatory affairs for the pharmaceutical and biotech industries. With over 30 years of operation, the company offers end-to-end support for drug development, including strategic planning, clinical trial design, data analysis, and regulatory submission compilation. Its core value proposition lies in deep technical expertise across numerous therapeutic areas and a proprietary regulatory review tool designed to identify gaps in development programs. The firm operates as a strategic partner to sponsors, helping to navigate complex FDA processes and accelerate product development.
Anti-Microbials and SepsisAnesthetics and AnesthesiaCardiovascularDermatologyEndocrine and MetabolismGastrointestinal and CoagulationGenitourinaryHormone Replacement TherapyIn vivo Diagnostic AgentsNeuropharmacologyNSAIDS/AnalgesicsOncologyOphthalmologyPulmonary and AllergyVaccines
Technology Platform
Proprietary regulatory and technical review tool used to perform gap analysis for drug development programs, evaluating compliance and identifying deficiencies against regulatory requirements.
Opportunities
Growing complexity in global regulatory submissions (e.g., eCTD, CDISC) and the rise of virtual biotechs without in-house expertise create sustained demand for high-end consulting.
Productizing its proprietary gap analysis tool could allow Hurley to scale its offering beyond traditional consulting hours and reach new clients digitally.
Risk Factors
Revenue is tied to client R&D budgets, which are cyclical and project-based, creating potential volatility.
Intense competition from large global CROs and niche consultancies pressures pricing and necessitates continuous differentiation.
The firm's heavy reliance on human expertise makes it vulnerable to talent attrition and succession challenges.
Competitive Landscape
Hurley competes in a fragmented market including large, full-service CROs (IQVIA, ICON, PRA), specialized regulatory affairs consultancies, and the internal teams of large pharmaceutical companies. Its differentiation is based on deep, integrated expertise over a 30-year period and a proprietary analytical tool, positioning it as a high-touch strategic partner rather than a commoditized service provider.
